{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T23:40:30Z","timestamp":1792539630169,"version":"4.5.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T00:00:00Z","timestamp":1792540800000},"content-version":"vor","delay-in-days":89,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"National High Level Hospital Clinical Research Funding"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-026-01570-3","type":"journal-article","created":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T13:26:30Z","timestamp":1784899590000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A multicentre phase III clinical trial of dual-epigenetic therapy plus CHOP compared with CHOP in previously untreated patients with peripheral T-cell lymphoma"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9690-8555","authenticated-orcid":false,"given":"Chong","family":"Wei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liping","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5057-5919","authenticated-orcid":false,"given":"Xiaobo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ningbin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyan","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aijun","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9730-9917","authenticated-orcid":false,"given":"Zhiming","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1592-1932","authenticated-orcid":false,"given":"Daobin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9489-5965","authenticated-orcid":false,"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,24]]},"reference":[{"key":"1570_CR1","doi-asserted-by":"publisher","unstructured":"Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IBO, Berti E, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia. 2022;36:1720-48. Epub 2022 Jun 22. Erratum in: Leukemia. 2023;37:1944\u20131951. https:\/\/doi.org\/10.1038\/s41375-023-01962-5.","DOI":"10.1038\/s41375-023-01962-5"},{"key":"1570_CR2","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1309\/AJCP7YLTQPUSDQ5C","volume":"138","author":"J Sun","year":"2012","unstructured":"Sun J, Yang Q, Lu Z, He M, Gao L, Zhu M, et al. Distribution of lymphoid neoplasms in China: analysis of 4,638 cases according to the World Health Organization classification. Am J Clin Pathol. 2012;138:429\u201334.","journal-title":"Am J Clin Pathol"},{"key":"1570_CR3","doi-asserted-by":"crossref","unstructured":"Liu W, Ji X, Song Y, Wang X, Zheng W, Lin N, et al. Improving survival of 3760 patients with lymphoma: Experience of an academic center over two decades. Cancer Med. 2020;9:3765-74.","DOI":"10.1002\/cam4.3037"},{"key":"1570_CR4","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/S0140-6736(18)32984-2","volume":"393","author":"S Horwitz","year":"2019","unstructured":"Horwitz S, O\u2019Connor OA, Pro B, Illidge T, Fanale M, Advani R, et al. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. Lancet. 2019;393:229\u201340.","journal-title":"Lancet"},{"key":"1570_CR5","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1182\/blood-2014-04-573089","volume":"124","author":"F Ellin","year":"2014","unstructured":"Ellin F, Landstr\u00f6m J, Jerkeman M, Relander T. Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry. Blood. 2014;124:1570\u20137.","journal-title":"Blood"},{"key":"1570_CR6","doi-asserted-by":"publisher","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","volume":"26","author":"J Vose","year":"2008","unstructured":"Vose J, Armitage J, Weisenburger D. International T-Cell Lymphoma Project. International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26:4124\u201330.","journal-title":"J Clin Oncol"},{"key":"1570_CR7","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1002\/ajh.24791","volume":"92","author":"JO Armitage","year":"2017","unstructured":"Armitage JO. The aggressive peripheral T-cell lymphomas: 2017. Am J Hematol. 2017;92:706\u201315.","journal-title":"Am J Hematol"},{"key":"1570_CR8","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1182\/blood-2013-10-531509","volume":"123","author":"O Odejide","year":"2014","unstructured":"Odejide O, Weigert O, Lane AA, Toscano D, Lunning MA, Kopp N, et al. A targeted mutational landscape of angioimmunoblastic T-cell lymphoma. Blood. 2014;123:1293\u20136.","journal-title":"Blood"},{"key":"1570_CR9","doi-asserted-by":"publisher","first-page":"e148","DOI":"10.3324\/haematol.2016.158428","volume":"102","author":"MP Dobay","year":"2017","unstructured":"Dobay MP, Lemonnier F, Missiaglia E, Bastard C, Vallois D, Jais JP, et al. Integrative clinicopathological and molecular analyses of angioimmunoblastic T-cell lymphoma and other nodal lymphomas of follicular helper T-cell origin. Haematologica. 2017;102:e148\u201351.","journal-title":"Haematologica"},{"key":"1570_CR10","doi-asserted-by":"publisher","first-page":"5827","DOI":"10.1182\/blood-2010-10-312603","volume":"117","author":"RL Piekarz","year":"2011","unstructured":"Piekarz RL, Frye R, Prince HM, Kirschbaum MH, Zain J, Allen SL, et al. Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. Blood. 2011;117:5827\u201334.","journal-title":"Blood"},{"key":"1570_CR11","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1093\/annonc\/mdv237","volume":"26","author":"Y Shi","year":"2015","unstructured":"Shi Y, Dong M, Hong X, Zhang W, Feng J, Zhu J, et al. Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma. Ann Oncol. 2015;26:1766\u201371.","journal-title":"Ann Oncol"},{"key":"1570_CR12","doi-asserted-by":"publisher","first-page":"841","DOI":"10.20892\/j.issn.2095-3941.2020.0413","volume":"18","author":"W Zhang","year":"2021","unstructured":"Zhang W, Su L, Liu L, Gao Y, Wang Q, Su H, et al. The combination of chidamide with the CHOEP regimen in previously untreated patients with peripheral T-cell lymphoma: a prospective, multicenter, single arm, phase 1b\/2 study. Cancer Biol Med. 2021;18:841\u20138.","journal-title":"Cancer Biol Med"},{"key":"1570_CR13","first-page":"2194","volume":"141","author":"J Ruan","year":"2023","unstructured":"Ruan J, Moskowitz A, Mehta-Shah N, Sokol L, Chen Z, Kotlov N, et al. Multicenter phase 2 study of oral azacitidine (CC-486) plus CHOP as initial treatment for PTCL. Blood. 2023;141:2194\u2013205.","journal-title":"Blood"},{"key":"1570_CR14","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32:3059\u201368.","journal-title":"J Clin Oncol"},{"key":"1570_CR15","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1182\/blood-2018-04-840538","volume":"132","author":"F Lemonnier","year":"2018","unstructured":"Lemonnier F, Dupuis J, Sujobert P, Tournillhac O, Cheminant M, Sarkozy C, et al. Treatment with 5-azacytidine induces a sustained response in patients with angioimmunoblastic T-cell lymphoma. Blood. 2018;132:2305\u20139.","journal-title":"Blood"},{"key":"1570_CR16","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1182\/blood.2020009004","volume":"137","author":"L Falchi","year":"2021","unstructured":"Falchi L, Ma H, Klein S, Lue JK, Montanari F, Marchi E, et al. Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: a multicenter phase 2 study. Blood. 2021;137:2161\u201370.","journal-title":"Blood"},{"key":"1570_CR17","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1200\/JCO.21.01815","volume":"40","author":"E Bachy","year":"2022","unstructured":"Bachy E, Camus V, Thieblemont C, Sibon D, Casasnovas RO, Ysebaert L, et al. Romidepsin Plus CHOP Versus CHOP in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Results of the Ro-CHOP Phase III Study (Conducted by LYSA). J Clin Oncol. 2022;40:242\u201351.","journal-title":"J Clin Oncol"},{"key":"1570_CR18","unstructured":"Wei C, Zhao DQ, Zhang Y, Wang W, Zhang W, Zhou DB. Prospective clinical study of chidamide combined with azacitidine in relapsed\/refractory angioimmunoblastic T-cell lymphoma. Chin J Oncol Prev Treat. 2023;15:51\u201355."},{"key":"1570_CR19","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.1491","volume":"14","author":"C Wei","year":"2024","unstructured":"Wei C, Wang W, Li W, Zhang Y, Zhao D, Zhang W, et al. Mutations of epigenetic genes and correlation with treatment response in peripheral T-cell lymphoma. Clin Transl Med. 2024;14:e1491. https:\/\/doi.org\/10.1002\/ctm2.1491.","journal-title":"Clin Transl Med"},{"key":"1570_CR20","doi-asserted-by":"publisher","first-page":"3093","DOI":"10.1200\/JCO.2011.40.2719","volume":"30","author":"F d\u2019Amore","year":"2012","unstructured":"d\u2019Amore F, Relander T, Lauritzsen GF, Jantunen E, Hagberg H, Anderson H, et al. Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01. J Clin Oncol. 2012;30:3093\u20139.","journal-title":"J Clin Oncol"},{"key":"1570_CR21","doi-asserted-by":"publisher","unstructured":"Park SI, Horwitz SM, Foss FM, Pinter-Brown LC, Carson KR, Rosen ST, et al. The role of autologous stem cell transplantation in patients with nodal peripheral T-cell lymphomas in first complete remission: Report from COMPLETE, a prospective, multicenter cohort study. Cancer. 2019 ;125:1507-17. Epub 2019 Jan 29. Erratum in: Cancer. 2019 Nov 1;125(21):3893. https:\/\/doi.org\/10.1002\/cncr.32467.","DOI":"10.1002\/cncr.32467"},{"key":"1570_CR22","doi-asserted-by":"publisher","first-page":"3061","DOI":"10.1007\/s00277-024-05708-w","volume":"103","author":"W Wang","year":"2024","unstructured":"Wang W, Zhang W, Su LP, Liu LH, Gao YH, Wang QS, et al. Efficacy of chidamide maintenance therapy versus autologous stem cell transplantation versus observation as a post-remission choice in the survival of adult patients with peripheral T-cell lymphoma: Post hoc analysis of a prospective, multicenter, phase 2 study in China. Ann Hematol. 2024;103:3061\u20139.","journal-title":"Ann Hematol"},{"key":"1570_CR23","doi-asserted-by":"publisher","first-page":"2867","DOI":"10.1038\/s41375-019-0473-1","volume":"33","author":"Y Watatani","year":"2019","unstructured":"Watatani Y, Sato Y, Miyoshi H, Sakamoto K, Nishida K, Gion Y, et al. Molecular heterogeneity in peripheral T-cell lymphoma, not otherwise specified revealed by comprehensive genetic profiling. Leukemia. 2019;33:2867\u201383.","journal-title":"Leukemia"},{"key":"1570_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101416","volume":"5","author":"YH Huang","year":"2024","unstructured":"Huang YH, Qiu YR, Zhang QL, Cai MC, Yu H, Zhang JM, et al. Genomic and transcriptomic profiling of peripheral T cell lymphoma reveals distinct molecular and microenvironment subtypes. Cell Rep Med. 2024;5:101416.","journal-title":"Cell Rep Med"},{"key":"1570_CR25","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1111\/bjh.70363","volume":"208","author":"C Wei","year":"2026","unstructured":"Wei C, Zhang Y, Zhao D, Zhang W, Zhou D. Clonal haematopoiesis in T-follicular helper cell lymphoma: A prognostic biomarker and early event in lymphoma evolution. Br J Haematol. 2026;208:1223\u201331.","journal-title":"Br J Haematol"},{"key":"1570_CR26","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/s41586-025-08871-w","volume":"642","author":"M Hosseini","year":"2025","unstructured":"Hosseini M, Voisin V, Chegini A, Varesi A, Cathelin S, Ayyathan DM, et al. Metformin reduces the competitive advantage of Dnmt3aR878H HSPCs. Nature. 2025;642:421\u201330.","journal-title":"Nature"},{"key":"1570_CR27","volume":"50","author":"MC Cai","year":"2024","unstructured":"Cai MC, Cheng S, Jing HM, Liu Y, Cui GH, Niu T, et al. Targeted agents plus CHOP compared with CHOP as the first-line treatment for newly diagnosed patients with peripheral T-cell lymphoma (GUIDANCE-03): an open-label, multicentre phase 2 clinical trial. Lancet Reg Health West Pac. 2024;50:101160.","journal-title":"Lancet Reg Health West Pac"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01570-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01570-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01570-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T23:20:00Z","timestamp":1792538400000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01570-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,24]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1570"],"URL":"https:\/\/doi.org\/10.1038\/s41408-026-01570-3","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,24]]},"assertion":[{"value":"8 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki and was approved by the institutional review board of Peking Union Medical College Hospital, Shanxi Cancer Hospital, The Second Hospital of Dalian Medical University, Central Hospital of Dalian University of Technology, Fujian Cancer Hospital, Jingzhou Hospital Affiliated to Yangtze University, Sheng Jing Hospital of China Medical University, Sun Yat-sen University Cancer Center, and Beijing Friendship Hospital.","order":2,"name":"Ethics","label":"Ethical approval and consent to participate","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"186"}}